G1 Therapeutics (NASDAQ:GTHX) Earns Buy Rating from HC Wainwright

G1 Therapeutics (NASDAQ:GTHXGet Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $9.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 113.27% from the stock’s current price.

GTHX has been the subject of several other reports. Wedbush reiterated an “outperform” rating and set a $5.00 target price (up from $4.00) on shares of G1 Therapeutics in a research report on Wednesday, February 28th. Needham & Company LLC reiterated a “buy” rating and set a $12.00 target price on shares of G1 Therapeutics in a research report on Wednesday, May 1st.

View Our Latest Stock Analysis on GTHX

G1 Therapeutics Price Performance

Shares of NASDAQ:GTHX opened at $4.22 on Wednesday. The company has a 50 day moving average of $4.28 and a 200 day moving average of $3.38. The stock has a market cap of $220.63 million, a P/E ratio of -6.81 and a beta of 1.71. G1 Therapeutics has a 12 month low of $1.08 and a 12 month high of $6.14. The company has a current ratio of 2.94, a quick ratio of 2.55 and a debt-to-equity ratio of 1.34.

G1 Therapeutics (NASDAQ:GTHXGet Free Report) last announced its earnings results on Wednesday, May 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). G1 Therapeutics had a negative net margin of 36.40% and a negative return on equity of 74.75%. The company had revenue of $14.48 million for the quarter, compared to the consensus estimate of $15.21 million. During the same quarter in the previous year, the firm earned ($0.53) earnings per share. As a group, sell-side analysts forecast that G1 Therapeutics will post -0.54 EPS for the current fiscal year.

Institutional Investors Weigh In On G1 Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Curi Wealth Management LLC lifted its holdings in shares of G1 Therapeutics by 17.8% in the 3rd quarter. Curi Wealth Management LLC now owns 70,742 shares of the company’s stock worth $102,000 after acquiring an additional 10,700 shares during the last quarter. Financial Advocates Investment Management bought a new stake in shares of G1 Therapeutics in the 4th quarter worth approximately $39,000. SG Americas Securities LLC bought a new stake in shares of G1 Therapeutics in the 1st quarter worth approximately $58,000. Creative Financial Designs Inc. ADV lifted its holdings in shares of G1 Therapeutics by 98.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 35,280 shares of the company’s stock worth $108,000 after acquiring an additional 17,475 shares during the last quarter. Finally, Capstone Investment Advisors LLC bought a new stake in shares of G1 Therapeutics in the 4th quarter worth approximately $76,000. 24.21% of the stock is currently owned by institutional investors.

G1 Therapeutics Company Profile

(Get Free Report)

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.

Recommended Stories

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.